Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2011

Open Access 01-12-2011 | Research

Inhibition of telomerase activity by HDV ribozyme in cancers

Authors: Yingying Lu, Junchao Gu, Dachuan Jin, Yanjing Gao, Mengbiao Yuan

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2011

Login to get access

Abstract

Background

Telomerase plays an important role in cell proliferation and carcinogenesis and is believed to be a good target for anti-cancer drugs. Elimination of template function of telomerase RNA may repress the telomerase activity.

Methods

A pseudo-knotted HDV ribozyme (g.RZ57) directed against the RNA component of human telomerase (hTR) was designed and synthesized. An in vitro transcription plasmid and a eukaryotic expression plasmid of ribozyme were constructed. The eukaryotic expression plasmid was induced into heptocellular carcinoma 7402 cells, colon cancer HCT116 cells and L02 hepatocytes respectively. Then we determine the cleavage activity of ribozyme against human telomerase RNA component (hTR) both in vitro and in vivo, and detect telomerase activity continuously.

Results

HDV ribozyme showed a specific cleavage activity against the telomerase RNA in vitro. The maximum cleavage ratio reached about 70.4%. Transfection of HDV ribozyme into 7402 cells and colon cancer cells HCT116 led to growth arrest and the spontaneous apoptosis of cells, and the telomerase activity dropped to 10% of that before.

Conclussion

HDV ribozyme (g.RZ57) is an effective strategy for gene therapy.
Appendix
Available only for authorised users
Literature
1.
Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA: Creation of human tumour cells with defined genetic elements. Nature. 1999, 400: 464-68. 10.1038/22780.CrossRefPubMed
2.
González-Suárez E, Samper E, Ramírez A, Flores JM, Martín-Caballero J, Jorcano JL, Blasco MA: Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 2001, 20: 2619-30.PubMedCentralCrossRefPubMed
3.
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science. 1994, 266 (5193): 2011-5. 10.1126/science.7605428.CrossRefPubMed
4.
Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, et al: The RNA component of human telomerase. Science. 1995, 269: 1236-41. 10.1126/science.7544491.CrossRefPubMed
5.
Mitchell JR, Wood E, Collins K: A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 1999, 402 (6761): 551-5. 10.1038/990141.CrossRefPubMed
6.
Yeo M, Rha SY, Jeung HC, Hu SX, Yang SH, Kim YS, An SW, Chung HC: Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. Int J Cancer. 2005, 114 (3): 484-9. 10.1002/ijc.20720.CrossRefPubMed
7.
Nosrati M, Li S, Bagheri S, Ginzinger D, Blackburn EH, Debs RJ, Kashani-Sabet M: Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA. Clin Cancer Res. 2004, 10 (15): 4983-90. 10.1158/1078-0432.CCR-04-0134.CrossRefPubMed
8.
Theimer CA, Blois CA, Feigon J: Structure of the human telomerase RNA pseudoknot reveals conserved tertiary interactions essential for function. Mol Cell. 2005, 17 (5): 671-82. 10.1016/j.molcel.2005.01.017.CrossRefPubMed
9.
Jeong S, Sefcikova J, Tinsley RA, Rueda D, Walter NG: Trans-acting hepatitis delta virus ribozyme: catalytic core and global structure are dependent on the 5' substrate sequence. Biochemistry. 2003, 42 (25): 7727-40. 10.1021/bi034627g.CrossRefPubMed
10.
Roy GA, Perealt JP: Delta ribozyme has the ability to cleave in trans mRNA. Nucleic Acids Res. 1999, 27 (4): 924-48. 10.1093/nar/27.4.942.CrossRef
11.
Gondert ME, Tinsley RA, Rueda D, Walter NG: Catalytic core structure of the trans-acting HDV ribozyme is subtly influenced by sequence variation outside the core. Biochemistry. 2006, 45 (24): 7563-73. 10.1021/bi052116j.CrossRefPubMed
12.
Nishikawa F, Roy M, Fauzi H, Nishikawa S: Detailed analysis of stem I and its 5' and 3' neighbor regions in the trans-acting HDV ribozyme. Nucleic Acids Res. 1999, 27 (2): 403-10. 10.1093/nar/27.2.403.PubMedCentralCrossRefPubMed
13.
Jeong S, Sefcikova J, Tinsley RA, Rueda D, Walter NG: Trans-acting hepatitis delta virus ribozyme: catalytic core and global structure are dependent on the 5' substrate sequence. Biochemistry. 2003, 42 (25): 7727-40. 10.1021/bi034627g.CrossRefPubMed
14.
Fauzi H, Kawakami J, Nishikawa F, et al: Analysis of the cleavage reaction of a trans--acting human hepatitis delta virus ribozyme [J]. Nucleic Acids Res. 1997, 25 (15): 3124-30. 10.1093/nar/25.15.3124.PubMedCentralCrossRefPubMed
15.
Hori T, Guo F, Tanaka Y, Uesugi S: Design and properties of trans-acting HDV ribozymes with extended substrate recognition regions. Nucleic Acids Res Suppl. 2001, 201-2. 1
16.
Nishikawa F, Fauzi H, Nishikawa S: Detailed analysis of base preferences at the cleavage site of a transacting HDV ribozyme: a mutation that changes cleavage site specificity. Nucleic Acids Res. 1997, 25 (8): 1605-10. 10.1093/nar/25.8.1605.PubMedCentralCrossRefPubMed
17.
Corey DR: Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene. 2002, 21 (4): 631-7. 10.1038/sj.onc.1205063. 10. Bisoffi M, Chakerian AE, Fore ML, Bryant JE, Hernandez JP, Moyzis RK, Griffith JK. Inhibition of human telomerase by a retrovirus expressing telomeric antisense RNA, Eur. J. Cancer. 1998, 34(8): 1242-9CrossRefPubMed
18.
Naka K, Yokozaki H, Yasui W, Tahara H, Tahara E, Tahara E: Effect of antisense human telomerase RNA transfection on the growth of human gastric cancer cell lines. Biochem Biophys Res Commun. 1999, 255: 753-58. 10.1006/bbrc.1998.9938.CrossRefPubMed
19.
20.
Romero DP, Blackburn EH: A conserved secondary structure for telomerase RNA. Cell. 1991, 67 (2): 343-53. 10.1016/0092-8674(91)90186-3.CrossRefPubMed
21.
Autexier C, Greider CW: Functional reconstitution of wild-type and mutant Tetrahymena telomerase. Genes Dev. 1994, 8 (5): 563-75. 10.1101/gad.8.5.563.CrossRefPubMed
22.
Fauzi H, Kawakami J, Nishikawa F, Nishikawa S: Analysis of the cleavage reaction of a trans-acting human hepatitis delta virus ribozyme. Nucleic Acids Res. 1997, 25 (15): 3124-30. 10.1093/nar/25.15.3124.PubMedCentralCrossRefPubMed
23.
Sirinart A, Perreault JP: Substrate specificity of delta ribozyme cleavage. J Biol Chem. 1998, 273 (21): 13182-88. 10.1074/jbc.273.21.13182.CrossRef
24.
Tomlinson RL, Ziegler TD, Supakorndej T, Terns RM, Terns MP: Cell cycle-regulated trafficking of human telomerase to telomeres. Mol Biol Cell. 2006, 17 (2): 955-65. 10.1091/mbc.E05-09-0903.PubMedCentralCrossRefPubMed
25.
Bailin LIU, Yi QU, Shuqiu LIU, Xuesong Ouyang: Inhibition of telomerase in tumor cells by ribozyme targeting telomerase RNA component SCIENCE IN CHINA (Series C). 2002, 45 (1): 87-95.
26.
Kruk PA, Orren DK, Bohr VA: Telomerase is elevated in early S phase in hamster cells, Biochem. Biophys Res Commun. 1997, 233: 712-22.CrossRef
27.
Griffith JD, Comeau L, Rosenfield S, Stansel RM, Biachi A, Moss H, deLange T: Mammalian telomeres end in a large duplex loop. Cell. 1999, 97: 503-514. 10.1016/S0092-8674(00)80760-6.CrossRefPubMed
28.
Wyllie Fiona, Jones Christopher, Skinner Julia, Haughton Michele, Wallis Corrin, Wynford-Thomas David, Faragher Richard, Kipling David: Telomerase prevents the accelerated cell aging of Werner syndrome fibroblasts. Nat Genet. 2000, 24: 16-17. 10.1038/71630.CrossRefPubMed
29.
Ren JG, Xia HL, Tian YM, Just T, Cai GP, Dai YR: Expression of telomerase inhibits hydroxyl radical-induced apoptosis in normal telomerase negative human lung fibroblast. FEBS Lett. 2001, 488: 133-38. 10.1016/S0014-5793(00)02397-8.CrossRefPubMed
30.
Jiang Xiuyun, Wilford Casey, Duensing Stephan, Munger Karl, Jones Grace, Jones Davy: Participation of Survivin in mitotic and apoptotic activities of normal and tumor-derived cells. J Cell Biochem. 2001, 83: 342-354. 10.1002/jcb.1228.CrossRefPubMed
31.
Monzó Mariano, Rosell Rafael, Felip Enriqueta, Astudillo Julio, ánchez Javier José, Maestre José, Martín Cristina, Font Albert, Barnadas Agustí, Abad Albert: A novel anti - apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small - cell lung cancers. J Clin Oncol. 1997, 17: 2100-2104.
32.
Zhu H, Fu W, Mattson MP: The catalytic subunit of telomerase protects neurons against amyloid beta-peptide-induced apoptosis. J Neurochem. 2000, 75: 117-124. 10.1046/j.1471-4159.2000.0750117.x.CrossRefPubMed
33.
Holt SE, Glinsky VV, Ivanova AB, Glinsky GV: Resistance to apoptosis in human cells conferred by telomerase function and telomerase stability. Mol Carcinog. 1999, 25: 241-48. 10.1002/(SICI)1098-2744(199908)25:4<241::AID-MC2>3.0.CO;2-9.CrossRefPubMed
34.
Qin LX, Tang ZY: The prognostic molecular markers in heptocellular carcinoma. World J Gastroenterol. 2002, 8 (3): 385-92.PubMed
Metadata
Title
Inhibition of telomerase activity by HDV ribozyme in cancers
Authors
Yingying Lu
Junchao Gu
Dachuan Jin
Yanjing Gao
Mengbiao Yuan
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2011
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-30-1

Other articles of this Issue 1/2011

Journal of Experimental & Clinical Cancer Research 1/2011 Go to the issue

Research

miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level

Research

Application of Benchtop-magnetic resonance imaging in a nude mouse tumor model

Research

Promising cytotoxic activity profile of fermented wheat germ extract (Avemar®) in human cancer cell lines

Research

Different patterns of NF-κB and Notch1 signaling contribute to tumor-induced lymphangiogenesis of esophageal squamous cell carcinoma

Research

IsoBED: a tool for automatic calculation of biologically equivalent fractionation schedules in radiotherapy using IMRT with a simultaneous integrated boost (SIB) technique

Review

The association of Streptococcus bovis/gallolyticus with colorectal tumors: The nature and the underlying mechanisms of its etiological role
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits